Market Overview:
The global human bacterial vaccine market is expected to grow at a CAGR of 7.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of infectious diseases, increasing demand for preventive vaccines, and technological advancements in the field of vaccine development. Based on type, the global human bacterial vaccine market is segmented into clostridium tetani, pertussis, haemophilus influenzae type b (Hib), streptococcus pneumoniae (pneumococcal), salmonella typhi (typhoid fever), bacillus anthracis (anthrax), and others. Based on application, the market is segmented into children, adults, and elderly. Geographically, the global human bacterial vaccine market is segmented into North America, Latin America,, Europe,, Asia Pacific,, and Middle East & Africa).
Product Definition:
A human bacterial vaccine is a vaccine that uses bacteria to help the body build immunity to specific diseases. Human bacterial vaccines are used to prevent or treat infections caused by bacteria. The importance of human bacterial vaccines is that they can help protect people from serious and life-threatening infections.
Clostridium Tetani:
Clostridium tetani is an infectious disease caused by gram-positive bacteria. The most common symptoms include fever, nausea, and vomiting. In severe cases, the infection may cause respiratory problems such as pneumonia or even death. It primarily affects the elderly population due to their decreased immune response and weak defense mechanism against bacterial infections.
Pertussis:
Pertussis is a respiratory disease caused by bacteria. The disease is named after the 18th century English physician, Dr. Edward Payson (1753-1823). According to the World Health Organization (WHO), globally around 10 million people contract this disease every year and about 150,000 deaths are recorded each year due to it. In developed countries such as U.S., Canada and U.K.
Application Insights:
Based on the application, the global market is segmented into children, adults and elderly. The children segment held a major share in 2015 owing to increasing incidence of diseases such as chickenpox and typhoid among kids. Moreover, rising number of pediatric surgeries is also expected to contribute towards growth during forecast period. In addition to this factor, growing usage of vaccines for kids coupled with high demand for immunization against cholera will further boost industry growth over the coming years.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the fact that there is a higher incidence of bacterial infections, which makes people vulnerable and susceptible to contract these vaccines. Moreover, government initiatives for immunization drives are also responsible for its large share in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising incidences of bacterial infections as well as increasing target population base due to high birth rate and aging demographics. The growing prevalence of chronic diseases such as diabetes has also increased demand for human bacterial vaccines significantly over this region's projected period.
Growth Factors:
- Increasing incidence of bacterial infections: The increasing incidence of bacterial infections is one of the key growth drivers for the human bacterial vaccine market. According to a study by the Centers for Disease Control and Prevention (CDC), every year in the U.S., there are about 2 million cases of antibiotic-resistant bacteria, which leads to around 23,000 deaths. This growing incidence of antibiotic-resistant bacteria is expected to drive demand for human bacterial vaccines in the coming years.
- Growing awareness about benefits of vaccination: There is a growing awareness among people about the benefits of vaccination, which is expected to boost demand for human bacterial vaccines in the coming years. According to a study by MarketsandMarkets,the global human vaccine market was valued at USD 33.90 billion in 2016 and is projected to reach USD 49.10 billion by 2023, at a CAGRof 7% from 2017to 2023 . This growing awareness about vaccinations is expected to propel demand for human bacterial vaccines over the next few years
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Bacterial Vaccine Market Research Report
By Type
Clostridium Tetani, Pertussis, Haemophilus Influenzae, Streptococcus Pneumoniae, Salmonella Typhi, Bacillus Anthracis, Others
By Application
Children, Adults, Elderly
By Companies
Merck, Sanofi, GSK, Mitsubishi Tanabe Pharma, Pfizer, Bayer, Emergent BioSolutions
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Human Bacterial Vaccine Market Report Segments:
The global Human Bacterial Vaccine market is segmented on the basis of:
Types
Clostridium Tetani, Pertussis, Haemophilus Influenzae, Streptococcus Pneumoniae, Salmonella Typhi, Bacillus Anthracis, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Children, Adults, Elderly
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Sanofi
- GSK
- Mitsubishi Tanabe Pharma
- Pfizer
- Bayer
- Emergent BioSolutions
Highlights of The Human Bacterial Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Clostridium Tetani
- Pertussis
- Haemophilus Influenzae
- Streptococcus Pneumoniae
- Salmonella Typhi
- Bacillus Anthracis
- Others
- By Application:
- Children
- Adults
- Elderly
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Bacterial Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A human bacterial vaccine is a vaccine that uses the body's own immune system to help protect against infection by bacteria. Human bacterial vaccines are often used to prevent infections caused by certain types of bacteria, such as Streptococcus pneumoniae or Haemophilus influenzae.
Some of the major companies in the human bacterial vaccine market are Merck, Sanofi, GSK, Mitsubishi Tanabe Pharma, Pfizer, Bayer, Emergent BioSolutions.
The human bacterial vaccine market is expected to register a CAGR of 7.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human Bacterial Vaccine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Human Bacterial Vaccine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Human Bacterial Vaccine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Human Bacterial Vaccine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Human Bacterial Vaccine Market Size & Forecast, 2018-2028
4.5.1 Human Bacterial Vaccine Market Size and Y-o-Y Growth
4.5.2 Human Bacterial Vaccine Market Absolute $ Opportunity
Chapter 5 Global Human Bacterial Vaccine Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Human Bacterial Vaccine Market Size Forecast by Type
5.2.1 Clostridium Tetani
5.2.2 Pertussis
5.2.3 Haemophilus Influenzae
5.2.4 Streptococcus Pneumoniae
5.2.5 Salmonella Typhi
5.2.6 Bacillus Anthracis
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Human Bacterial Vaccine Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Human Bacterial Vaccine Market Size Forecast by Applications
6.2.1 Children
6.2.2 Adults
6.2.3 Elderly
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Human Bacterial Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Human Bacterial Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Human Bacterial Vaccine Analysis and Forecast
9.1 Introduction
9.2 North America Human Bacterial Vaccine Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Human Bacterial Vaccine Market Size Forecast by Type
9.6.1 Clostridium Tetani
9.6.2 Pertussis
9.6.3 Haemophilus Influenzae
9.6.4 Streptococcus Pneumoniae
9.6.5 Salmonella Typhi
9.6.6 Bacillus Anthracis
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Human Bacterial Vaccine Market Size Forecast by Applications
9.10.1 Children
9.10.2 Adults
9.10.3 Elderly
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Human Bacterial Vaccine Analysis and Forecast
10.1 Introduction
10.2 Europe Human Bacterial Vaccine Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Human Bacterial Vaccine Market Size Forecast by Type
10.6.1 Clostridium Tetani
10.6.2 Pertussis
10.6.3 Haemophilus Influenzae
10.6.4 Streptococcus Pneumoniae
10.6.5 Salmonella Typhi
10.6.6 Bacillus Anthracis
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Human Bacterial Vaccine Market Size Forecast by Applications
10.10.1 Children
10.10.2 Adults
10.10.3 Elderly
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Human Bacterial Vaccine Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Human Bacterial Vaccine Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Human Bacterial Vaccine Market Size Forecast by Type
11.6.1 Clostridium Tetani
11.6.2 Pertussis
11.6.3 Haemophilus Influenzae
11.6.4 Streptococcus Pneumoniae
11.6.5 Salmonella Typhi
11.6.6 Bacillus Anthracis
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Human Bacterial Vaccine Market Size Forecast by Applications
11.10.1 Children
11.10.2 Adults
11.10.3 Elderly
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Human Bacterial Vaccine Analysis and Forecast
12.1 Introduction
12.2 Latin America Human Bacterial Vaccine Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Human Bacterial Vaccine Market Size Forecast by Type
12.6.1 Clostridium Tetani
12.6.2 Pertussis
12.6.3 Haemophilus Influenzae
12.6.4 Streptococcus Pneumoniae
12.6.5 Salmonella Typhi
12.6.6 Bacillus Anthracis
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Human Bacterial Vaccine Market Size Forecast by Applications
12.10.1 Children
12.10.2 Adults
12.10.3 Elderly
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Human Bacterial Vaccine Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Human Bacterial Vaccine Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Human Bacterial Vaccine Market Size Forecast by Type
13.6.1 Clostridium Tetani
13.6.2 Pertussis
13.6.3 Haemophilus Influenzae
13.6.4 Streptococcus Pneumoniae
13.6.5 Salmonella Typhi
13.6.6 Bacillus Anthracis
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Human Bacterial Vaccine Market Size Forecast by Applications
13.10.1 Children
13.10.2 Adults
13.10.3 Elderly
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Human Bacterial Vaccine Market: Competitive Dashboard
14.2 Global Human Bacterial Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 Sanofi
14.3.3 GSK
14.3.4 Mitsubishi Tanabe Pharma
14.3.5 Pfizer
14.3.6 Bayer
14.3.7 Emergent BioSolutions
